Abstract: A method of measuring immunocompetence is described. This method provides a means for assessing the effects of diseases or conditions that compromise the immune system and of therapies aimed to reconstitute it. This method is based on quantifying T-cell diversity by calculating the number of diverse T-cell receptor (TCR) beta chain variable regions from blood cells.
Type:
Application
Filed:
December 3, 2013
Publication date:
July 10, 2014
Applicant:
Fred Hutchinson Cancer Research Center
Inventors:
Harlan S. Robins, Edus H. Warren, III, Christopher Scott Carlson
Abstract: Methods for treating or preventing radiocontrast agent induced kidney injury in a mammal are disclosed, the methods comprising administering to the mammal a first effective amount of a chalcogenide composition prior to administering a radiocontrast agent to the mammal.
Abstract: Compositions and methods are described for highly sensitive quantification of the relative representation of DNA from adaptive immune cells (e.g., T and/or B lymphocytes) in DNA extracted from complex mixtures of cells that include cells which are not adaptive immune cells. Included are methods for determining the relative presence in a tumor of tumor infiltrating lymphocytes (TIL), the relative presence of lymphocytes infiltrating a somatic tissue that is the target of an autoimmune disease, and the relative presence of lymphocytes infiltrating a transplanted organ.
Type:
Application
Filed:
March 6, 2014
Publication date:
July 3, 2014
Applicants:
Fred Hutchinson Cancer Research Center, Adaptive Biotechnologies Corporation
Inventors:
Harlan S. Robins, Robert J. Livingston, Jason H. Bielas
Abstract: The present invention provides compositions and methods for DNA targeting using TAL effectors and TAL effector based proteins, including but not limited to targeted gene regulation and targeted cleavage of cellular chromatin in a region of interest and/or homologous recombination at a predetermined site in cells. Compositions include fusion polypeptides comprising a TAL effector or a TAL effector binding domain in combination with other domains, including but not limited to a cleavage domain. The TAL effector binding domain includes modifications that increase activity of the same and also remove the constraints that the DNA target sequence be preceded by a thymine.
Type:
Application
Filed:
January 3, 2013
Publication date:
July 3, 2014
Applicants:
Fred Hutchinson Cancer Research Center, Iowa State University Research Foundation, Inc.
Inventors:
Adam Joseph Bogdanove, Barry Leonard Stoddard, Philip H. Bradley, Erin Lynn Doyle
Abstract: Methods and systems for discovering drug candidates are disclosed. Methods and systems can include generating libraries of potential drug candidates (e.g., libraries of peptides) that can be screened to identify sub-libraries of potential drug candidates (e.g., sub-libraries of peptides) having selected pharmacological properties. Methods of making and using peptide libraries are also provided. D-amino acid chlorotoxins and D-amino acid chlorotoxin variants are also provided.
Type:
Application
Filed:
December 10, 2013
Publication date:
June 26, 2014
Applicant:
Fred Hutchinson Cancer Research Center
Inventors:
James Olson, Christopher Mehlin, Mark Stroud, Julian Simon, Colin Correnti, Patrick Paddison, Roland Strong, Damon May
Abstract: A fluid delivery device includes an array of needles, each in fluid communication with a respective reservoir. Respective actuators are coupled so as to be operable to drive fluid from the reservoirs via needle ports. Each needle can have a plurality of ports, and the ports can be arranged to deliver a substantially equal amount of fluid at any given location along its length. A driver is coupled to the actuators to selectively control the rate, volume, and direction of flow of fluid through the needles. The device can simultaneously deliver a plurality of fluid agents along respective axes in solid tissue in vivo. If thereafter resected, the tissue can be sectioned for evaluation of an effect of each agent on the tissue, and based on the evaluation, candidate agents selected or deselected for clinical trials or therapy, and subjects selected or deselected for clinical trials or therapeutic treatment.
Type:
Application
Filed:
February 11, 2014
Publication date:
June 12, 2014
Applicant:
Fred Hutchinson Cancer Research Center
Inventors:
S. Bahram Bahrami, Mandana Veiseh, James M. Olson
Abstract: A fluid delivery device includes an array of needles, each in fluid communication with a respective reservoir. Respective actuators are coupled so as to be operable to drive fluid from the reservoirs via needle ports. Each needle can have a plurality of ports, and the ports can be arranged to deliver a substantially equal amount of fluid at any given location along its length. A driver is coupled to the actuators to selectively control the rate, volume, and direction of flow of fluid through the needles. The device can simultaneously deliver a plurality of fluid agents along respective axes in solid tissue in vivo. If thereafter resected, the tissue can be sectioned for evaluation of an effect of each agent on the tissue, and based on the evaluation, candidate agents selected or deselected for clinical trials or therapy, and subjects selected or deselected for clinical trials or therapeutic treatment.
Type:
Application
Filed:
February 11, 2014
Publication date:
June 12, 2014
Applicant:
Fred Hutchinson Cancer Research Center
Inventors:
S. Bahram Bahrami, Mandana Veiseh, James M. Olson
Abstract: The present invention provides compositions and methods of identifying a subject as having an increased risk of developing fragile X-associated tremor and ataxia syndrome (FXTAS) or identifying a subject having an increased risk of developing fragile X syndrome (FXS), comprising analyzing messenger RNA (mRNA) transcripts and/or translation products of the antisense gene ASFMR1.
Type:
Application
Filed:
October 31, 2013
Publication date:
May 22, 2014
Applicant:
THE FRED HUTCHINSON CANCER RESEARCH CENTER
Inventors:
STEPHEN J. TAPSCOTT, GALINA N. FILIPPOVA, PAULA D. LADD
Abstract: Compositions and methods are provided for preventing or attenuating cancer progression or blocking metastasis in prostate cancer and other cancers (e.g., ovarian carcinoma, endometrial cancer, renal cell carcinoma) that are characterized by overexpression of the type II cell surface serine protease hepsin, based on the discovery of multiple disclosed compounds having activity as specific hepsin inhibitors.
Type:
Application
Filed:
January 16, 2014
Publication date:
May 8, 2014
Applicant:
Fred Hutchinson Cancer Research Center
Inventors:
Valeri I. Vasioukhin, John R. Chevillet
Abstract: The present invention provides methods of reducing the cytotoxic effects of nitric oxide and sulfides comprising coadministering nitric oxide with sulfide. In addition, the present invention provides novel pharmaceutical compositions comprising both nitric oxide and sulfide. The methods and compositions of the present invention may be used in the treatment or prevention of a variety of diseases and disorders, and also in the prevention of cell or tissue damage, including that resulting from ischemia or hypoxia.
Abstract: Compositions and methods of treating or preventing disease or injury to a human patient or biological material undergoing ischemic or hypoxic conditions.
Type:
Grant
Filed:
February 11, 2011
Date of Patent:
March 25, 2014
Assignee:
Fred Hutchinson Cancer Research Center
Inventors:
Fuqiang Ruan, Edward A. Wintner, Thomas L. Deckwerth
Abstract: A fluid delivery device includes an array of needles, each in fluid communication with a respective reservoir. Respective actuators are coupled so as to be operable to drive fluid from the reservoirs via needle ports. Each needle can have a plurality of ports, and the ports can be arranged to deliver a substantially equal amount of fluid at any given location along its length. A driver is coupled to the actuators to selectively control the rate, volume, and direction of flow of fluid through the needles. The device can simultaneously deliver a plurality of fluid agents along respective axes in solid tissue in vivo. If thereafter resected, the tissue can be sectioned for evaluation of an effect of each agent on the tissue, and based on the evaluation, candidate agents selected or deselected for clinical trials or therapy, and subjects selected or deselected for clinical trials or therapeutic treatment.
Type:
Grant
Filed:
December 19, 2011
Date of Patent:
March 18, 2014
Assignee:
Fred Hutchinson Cancer Research Center
Inventors:
S. Bahram Bahrami, Mandana Veiseh, James Olson
Abstract: Compositions and methods are provided for preventing or attenuating cancer progression or blocking metastasis in prostate cancer and other cancers (e.g., ovarian carcinoma, endometrial cancer, renal cell carcinoma) that are characterized by overexpression of the type II cell surface serine protease hepsin, based on the discovery of multiple disclosed compounds having activity as specific hepsin inhibitors.
Type:
Grant
Filed:
April 30, 2013
Date of Patent:
March 4, 2014
Assignee:
Fred Hutchinson Cancer Research Center
Inventors:
Valeri I. Vasioukhin, John R. Chevillet
Abstract: A fluid delivery device includes an array of needles, each in fluid communication with a respective reservoir. Respective actuators are coupled so as to be operable to drive fluid from the reservoirs via needle ports. Each needle can have a plurality of ports, and the ports can be arranged to deliver a substantially equal amount of fluid at any given location along its length. A driver is coupled to the actuators to selectively control the rate, volume, and direction of flow of fluid through the needles. The device can simultaneously deliver a plurality of fluid agents along respective axes in solid tissue in vivo. If thereafter resected, the tissue can be sectioned for evaluation of an effect of each agent on the tissue, and based on the evaluation, candidate agents selected or deselected for clinical trials or therapy, and subjects selected or deselected for clinical trials or therapeutic treatment.
Type:
Grant
Filed:
December 19, 2011
Date of Patent:
February 25, 2014
Assignee:
Fred Hutchinson Cancer Research Center
Inventors:
S. Bahram Bahrami, Mandana Veiseh, James Olson
Abstract: A method of measuring immunocompetence is described. This method provides a means for assessing the effects of diseases or conditions that compromise the immune system and of therapies aimed to reconstitute it. This method is based on quantifying T-cell diversity by calculating the number of diverse T-cell receptor (TCR) beta chain variable regions from blood cells.
Type:
Grant
Filed:
June 4, 2010
Date of Patent:
February 4, 2014
Assignee:
Fred Hutchinson Cancer Research Center
Inventors:
Harlan S. Robins, Edus H. Warren, III, Christopher Scott Carlson
Abstract: The present invention provides compositions and methods of identifying a subject as having an increased risk of developing fragile X-associated tremor and ataxia syndrome (FXTAS) or identifying a subject having an increased risk of developing fragile X syndrome (FXS), comprising analyzing messenger RNA (mRNA) transcripts and/or translation products of the antisense gene ASFMR1.
Type:
Grant
Filed:
October 2, 2008
Date of Patent:
December 3, 2013
Assignee:
The Fred Hutchinson Cancer Research Center
Inventors:
Stephen J. Tapscott, Galina N. Filippova, Paula D. Ladd
Abstract: In one aspect, the present invention provides an intron-modified cap expression cassette useful for generating adeno-associated virus (AAV) vector particles. In another aspect, the present invention provides a method of reducing the immune response in a mammalian subject undergoing treatment with an AAV vector.
Type:
Application
Filed:
November 10, 2011
Publication date:
November 7, 2013
Applicant:
FRED HUTCHINSON CANCER RESEARCH CENTER
Inventors:
Arthur Dusty Miller, Christine L. Halbert, Michael J. Metzger
Abstract: Compositions and methods are described for highly sensitive quantification of the relative representation of DNA from adaptive immune cells (e.g., T and/or B lymphocytes) in DNA extracted from complex mixtures of cells that include cells which are not adaptive immune cells. Included are methods for determining the relative presence in a tumor of tumor infiltrating lymphocytes (TIL), the relative presence of lymphocytes infiltrating a somatic tissue that is the target of an autoimmune disease, and the relative presence of lymphocytes infiltrating a transplanted organ.
Type:
Application
Filed:
October 19, 2012
Publication date:
October 31, 2013
Applicants:
FRED HUTCHINSON CANCER RESEARCH CENTER, ADAPTIVE BIOTECHNOLOGIES CORPORATION
Inventors:
ADAPTIVE BIOTECHNOLOGIES CORPORATION, FRED HUTCHINSON CANCER RESEARCH CEN
Abstract: In one aspect, the invention provides a method of screening a human subject to determine if said subject has a genetic predisposition to develop, or is suffering from Facioscapulohumeral Dystrophy (FSHD), said method comprising: (a) providing a biological sample comprising genomic DNA from the subject; and (b) analyzing the portion of the genomic DNA in the sample corresponding to the distal D4Z4-pLAM region on chromosome 4 and determining the presence or absence of a polymorphism resulting in a functional polyadenylation sequence operationally linked to exon 3 of the DUX4 gene, wherein a determination of the absence of a functional polyadenylation sequence operationally linked to exon 3 of the DUX4 gene indicates that the subject does not have a genetic predisposition to develop, and is not suffering from FSHD, and/or wherein a determination of the presence of a functional polyadenylation sequence operationally linked to exon 3 of the DUX4 gene indicates that the subject has a genetic predisposition to devel
Type:
Application
Filed:
August 18, 2011
Publication date:
October 31, 2013
Applicants:
Fred Hutchinson Cancer Research Center, University of Rochester Medical Center, Leiden University Medical Center
Inventors:
Silvere M. van der Maarel, Stephen J. Tapscott, Rabi Tawil, Richard J.L.F. Lemmers, Linda Geng, Lauren Snider
Abstract: A fluid-delivery device includes an array of needles. The needle can deposit a hollow and/or porous tube into a tissue of a subject, and the porous tube can contain one or more fluid agents. The hollow and/or porous tube can control the rate at which the agents diffuse into the tissue. The device can simultaneously deliver a plurality of porous tubes along parallel axes in a tissue in vivo. If thereafter resected, the tissue can be sectioned for evaluation of an effect of each agent on the tissue; based on the evaluation, candidate agents or subjects can be selected or deselected for clinical trials or therapy.